SCHEMBL10112372

SCHEMBL10112372

CC(=O)Oc1ccc(-c2cccnc2)nc1-c1ccc(Br)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.47
PKM P14618 1/20 0.47
RAB9A P51151 1/20 0.47
KDM4E B2RXH2 3/20 0.46
MAPT P10636 2/20 0.46
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
CYP19A1 P11511 2/20 0.45
TNF P01375 1/20 0.43
ABL1 P00519 1/20 0.42
BCR P11274 1/20 0.42
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
HSD17B10 Q99714 1/20 0.40
KMT2A Q03164 3/20 0.40
RXFP1 Q9HBX9 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
CFD P00746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10112350 0.78 CYP19A1 (0.52) NPC1SMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL10112352 0.78 CYP19A1 (0.52) NPC1SMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL830046 0.76 CYP19A1 (0.54) NPC1SMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL1316063 0.74 CFD (0.70) NPC1SMN1; SMN2TP53PKMRAB9A
SCHEMBL2216120 0.70 TSHR (0.49) NPC1SMN1; SMN2TP53PKMRAB9A
SCHEMBL2216123 0.68 NPC1 (0.67) NPC1SMN1; SMN2TP53PKMRAB9A
SCHEMBL6198427 0.68 RAB9A (0.64) NPC1SMN1; SMN2TP53RAB9AKDM4E
SCHEMBL10112447 0.67 TNF (0.47) MAPTTNF
SCHEMBL10112442 0.67 TNF (0.47) MAPTTNF
SCHEMBL24871232 0.67 CYP2A6 (0.57) NPC1SMN1; SMN2RAB9AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 NPC1 408/4885SMN1; SMN2 1789/4885TP53 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.